In the long term, the company is developing a plan to create more tests based on its technology, which digitizes blood samples and turns them into images.
The company released data showing that its panel detects early-stage liver cancer with 71 percent sensitivity compared to 25 percent for the standard test.
AlloSure 3.0 can diagnose the very early stages of T-cell mediated rejection, allowing clinicians to begin anti-rejection therapies and monitor treatment.
The researchers aimed to develop a test that could help clinicians determine whether a patient would respond to therapy, before the onset of treatment.
Rutgers researchers have developed a point-of-care tool that can rapidly assess the sensitivity of tumor cells to cancer drugs without staining or labeling.
